Company Filing History:
Years Active: 2013
Title: Michael Jonathan Bury: Innovator in TRPV4 Antagonists
Introduction
Michael Jonathan Bury is a notable inventor based in King of Prussia, Pennsylvania. He has made significant contributions to the field of pharmaceuticals, particularly in the development of TRPV4 antagonists. His work is characterized by a focus on innovative compounds that have the potential to impact medical treatments.
Latest Patents
Michael holds a patent for TRPV4 antagonists, which relates to diazabicyclo[2.2.1]hept-2-yl analogs. This patent includes pharmaceutical compositions containing these analogs and outlines their use as TRPV4 antagonists. His innovative approach in this area showcases his commitment to advancing pharmaceutical science.
Career Highlights
Michael is currently employed at GlaxoSmithKline LLC, a leading global healthcare company. His role at GlaxoSmithKline allows him to work on cutting-edge research and development projects that aim to improve patient outcomes through innovative therapies.
Collaborations
Throughout his career, Michael has collaborated with talented individuals such as Mui Cheung and Hilary Schenck Eidam. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Michael Jonathan Bury is a dedicated inventor whose work in TRPV4 antagonists exemplifies the spirit of innovation in the pharmaceutical industry. His contributions continue to pave the way for new therapeutic options.